LLY vs. NVDA: Eli Lilly vs. NVIDIA Stock Comparison
How do Eli Lilly (LLY) and NVIDIA (NVDA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Eli Lilly (LLY) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas NVIDIA (NVDA) belongs to Information Technology (Semiconductors & Semiconductor Equipment) — their GICS classifications point to very different parts of the market.
| Profile Item | LLY | NVDA |
|---|---|---|
| Name | Eli Lilly and Company | NVIDIA Corporation |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Information Technology |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Semiconductors & Semiconductor Equipment |
| GICS Industry | Pharmaceuticals | Semiconductors & Semiconductor Equipment |
| GICS Sub-Industry | Pharmaceuticals | Semiconductors |
| Market Capitalization | 1,057.35 billion USD | 5,424.54 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | June 1, 1972 | January 22, 1999 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | LLY | NVDA |
|---|---|---|
| Total Return (1Y) | 86.33% | 24.06% |
| Total Return (3Y, Annualized) | 38.69% | 70.32% |
| Total Return (5Y, Annualized) | 36.38% | 61.64% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
NVIDIA (NVDA) has a highly aggressive beta of 2.22, indicating much higher sensitivity to broad-market moves, while Eli Lilly (LLY) is defensive at 0.50 and tends to be less market-sensitive — a wide gap in beta profiles.
| Metric | LLY | NVDA |
|---|---|---|
| Volatility (1Y, Annualized) | 35.74% | 36.61% |
| Beta (5Y) | 0.50 | 2.22 |
| Max Drawdown (5Y) | -34.48% | -66.34% |
| Avg. Volume (3M) | 3.06M | 151.36M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | LLY | NVDA |
|---|---|---|
| Sharpe Ratio (1Y) | 2.30 | 0.55 |
| Sortino Ratio (1Y) | 4.03 | 0.80 |
Profitability
ROE (TTM)
Both companies show strong equity returns, but NVIDIA (NVDA) at 114.29% is the standout with ROE above its industry range; Eli Lilly (LLY) at 102.29% also sits in the top quartile.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
102.29%
- LLY
- 102.29%
- Max
- 102.29%
- Q3
- 2.88%
- Median
- -33.17%
- Q1
- -64.41%
- Min
- -157.61%
NVDA
Semiconductors & Semiconductor Equipment industry group
114.29%
- NVDA
- 114.29%
- Max
- 39.97%
- Q3
- 18.51%
- Median
- 7.57%
- Q1
- -3.88%
- Min
- -33.94%
Net Margin (TTM)
Both Eli Lilly (LLY) at 33.53% and NVIDIA (NVDA) at 62.97% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.53%
- LLY
- 33.53%
- Max
- 11.21%
- Q3
- 2.65%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -13.58%
NVDA
Semiconductors & Semiconductor Equipment industry group
62.97%
- NVDA
- 62.97%
- Max
- 57.64%
- Q3
- 24.50%
- Median
- 9.19%
- Q1
- -1.07%
- Min
- -32.92%
Operating Margin (TTM)
NVIDIA (NVDA) at 65.60% shows unusually strong operating efficiency — above its industry’s operating margin range — and Eli Lilly (LLY) at 54.22% also operates in the top quartile.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
54.22%
- Max
- 94.41%
- LLY
- 54.22%
- Q3
- 8.92%
- Median
- 0.00%
- Q1
- -119.39%
- Min
- -309.54%
NVDA
Semiconductors & Semiconductor Equipment industry group
65.60%
- NVDA
- 65.60%
- Max
- 48.99%
- Q3
- 22.53%
- Median
- 12.19%
- Q1
- 0.62%
- Min
- -23.39%
Profitability Metrics
| Metric | LLY | NVDA |
|---|---|---|
| ROE (TTM) | 102.29% | 114.29% |
| ROA (TTM) | 20.36% | 52.73% |
| Net Margin (TTM) | 33.53% | 62.97% |
| Operating Margin (TTM) | 54.22% | 65.60% |
| Gross Margin (TTM) | 83.40% | 74.15% |
Growth
Revenue Growth
NVIDIA (NVDA) at 65.47% clears its industry range for revenue growth, far stronger top-line momentum than Eli Lilly (LLY) at 44.70%, which is closer to a typical peer reading.
EPS Growth
Both Eli Lilly (LLY) at 95.99% and NVIDIA (NVDA) at 66.67% sit in the top peer quartile for EPS growth, so each is compounding per-share earnings faster than typical industry peers.
Growth Metrics
| Metric | LLY | NVDA |
|---|---|---|
| Revenue Growth (YoY) | 44.70% | 65.47% |
| Revenue Growth (3Y CAGR) | 31.69% | 100.05% |
| EPS Growth (YoY) | 95.99% | 66.67% |
| EPS Growth (3Y CAGR) | 51.71% | 204.24% |
Financial Strength
Current Ratio (MRQ)
NVIDIA (NVDA) at 3.44 keeps current ratio within its industry’s typical mid-range, while Eli Lilly (LLY) at 1.36 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for LLY.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.36
- Max
- 26.16
- Q3
- 12.25
- Median
- 5.88
- Q1
- 2.81
- LLY
- 1.36
- Min
- 0.55
NVDA
Semiconductors & Semiconductor Equipment industry group
3.44
- Max
- 10.33
- Q3
- 5.74
- NVDA
- 3.44
- Median
- 3.32
- Q1
- 2.37
- Min
- 1.07
Debt / Equity (MRQ)
NVIDIA (NVDA) at 0.07 carries an industry-typical debt-to-equity mix, while Eli Lilly (LLY) at 1.62 uses more debt funding than most peers.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.62
- Max
- 1.64
- LLY
- 1.62
- Q3
- 0.68
- Median
- 0.16
- Q1
- 0.02
- Min
- 0.00
NVDA
Semiconductors & Semiconductor Equipment industry group
0.07
- Max
- 1.44
- Q3
- 0.65
- Median
- 0.18
- NVDA
- 0.07
- Q1
- 0.04
- Min
- 0.00
Financial Strength Metrics
| Metric | LLY | NVDA |
|---|---|---|
| Current Ratio (MRQ) | 1.36 | 3.44 |
| Debt / Equity (MRQ) | 1.62 | 0.07 |
| Net Debt / EBITDA | 1.10 | -0.24 |
Dividends
Dividend Yield (TTM)
NVIDIA (NVDA) at 0.02% pays an industry-typical yield; Eli Lilly (LLY) at 0.54% is above its entire peer range — the higher number, but one that calls for a look at payout sustainability before treating it as an advantage.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.54%
- LLY
- 0.54%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NVDA
Semiconductors & Semiconductor Equipment industry group
0.02%
- Max
- 0.68%
- Q3
- 0.28%
- NVDA
- 0.02%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
NVIDIA (NVDA) at 0.61% keeps its payout in the industry’s typical band, while Eli Lilly (LLY) at 21.69% pays out more than any of its peers — the most stretched cover in its group.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.69%
- LLY
- 21.69%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NVDA
Semiconductors & Semiconductor Equipment industry group
0.61%
- Max
- 43.44%
- Q3
- 18.06%
- NVDA
- 0.61%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | LLY | NVDA |
|---|---|---|
| Dividend Yield (TTM) | 0.54% | 0.02% |
| Dividend Payout Ratio (TTM) | 21.69% | 0.61% |
Valuation
P/E Ratio (TTM)
NVIDIA (NVDA) at 33.58 sits in the cheaper P/E ratio quartile, while Eli Lilly (LLY) at 40.00 is closer to its industry’s usual earnings multiple — a discount for NVDA, though growth and earnings durability still matter.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.00
- Max
- 84.14
- Q3
- 43.16
- LLY
- 40.00
- Median
- 28.60
- Q1
- 15.80
- Min
- 2.32
NVDA
Semiconductors & Semiconductor Equipment industry group
33.58
- Max
- 163.81
- Q3
- 101.97
- Median
- 53.04
- Q1
- 39.19
- NVDA
- 33.58
- Min
- 11.79
P/S Ratio (TTM)
Eli Lilly (LLY) at 13.27 is priced about in line with its industry on P/S ratio, while NVIDIA (NVDA) at 21.40 sits in the pricier quartile — NVDA costs more per dollar of sales.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.27
- Max
- 70.39
- Q3
- 30.57
- LLY
- 13.27
- Median
- 7.62
- Q1
- 3.50
- Min
- 0.01
NVDA
Semiconductors & Semiconductor Equipment industry group
21.40
- Max
- 34.90
- NVDA
- 21.40
- Q3
- 19.10
- Median
- 8.95
- Q1
- 3.82
- Min
- 0.01
P/B Ratio (MRQ)
Measured against book value, both Eli Lilly (LLY) at 33.96 and NVIDIA (NVDA) at 27.75 look expensive — each P/B ratio sits above its industry’s benchmark range.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.96
- LLY
- 33.96
- Max
- 17.22
- Q3
- 8.05
- Median
- 3.87
- Q1
- 1.75
- Min
- -7.69
NVDA
Semiconductors & Semiconductor Equipment industry group
27.75
- NVDA
- 27.75
- Max
- 24.19
- Q3
- 11.73
- Median
- 6.28
- Q1
- 3.04
- Min
- 0.23
Valuation Metrics
| Metric | LLY | NVDA |
|---|---|---|
| P/E Ratio (TTM) | 40.00 | 33.58 |
| P/S Ratio (TTM) | 13.27 | 21.40 |
| P/B Ratio (MRQ) | 33.96 | 27.75 |
| Free Cash Flow Yield (TTM) | 1.05% | 0.85% |